<DOC>
	<DOCNO>NCT01088971</DOCNO>
	<brief_summary>Gut microflora-mucosal interaction may involve pathogenesis irritable bowel syndrome ( IBS ) . The purpose study investigate efficacy Duolac7S change colonic microflora improve symptom IBS sufferer . In , 64 patient Rome III positive diarrhea type IBS complete 6-week multiple centre control clinical trial . Patients randomize receive either 2 capsules/day Duolac7S 2 capsules/day placebo . IBS symptom monitor scored accord Likert scale . Changes faecal microflora , stool frequency form , quality life ( QOL ) score also monitor .</brief_summary>
	<brief_title>Effect Duolac 7S Administration Improving Symptom Irritable Bowel Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>age : 18~65 year diarrhea type irritable bowel syndrome ( ROME III criterion ) organic bowel disease ( colonoscopy barium enema ) pregnant woman nurse mother hypersensitivity probiotic congestive heart failure ischemic heart disease systolic blood pressure : 160 mmHg diastolic blood pressure : 100 mmHg uncontrolled diabetes mellitus , secondary dyslipidemia , hyperthyroidism , hypothyroidism abdominal surgery ( exception : appendectomy , hernia surgery ) moderate alcohol drinking</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>